By Fineline Cube China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving clinical approval for its pain relief drug HSK51155 from the National Medical Products Administration (NMPA), advancing the Nav1.8 inhibitor into clinical trials months after it was licensed to AbbVie in a blockbuster deal.
Approval Summary
| Item | Detail |
|---|---|
| Company | Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) |
| Product | HSK51155 |
| Drug Class | Nav1.8 inhibitor (selective sodium ion channel blocker) |
| Indication | Pain relief |
| Regulatory Status | Clinical approval granted by NMPA |
| Licensing Partner | AbbVie (April 2026 deal, potential total value > USD 700 million) |
| Announcement Date | 19 Aug 2026 |
Drug Profile – HSK51155
- Mechanism: A Nav1.8 inhibitor that selectively blocks specific sodium ion channels
- Pharmacology: Suppresses abnormal firing of pain‑sensing nerves and reduces pain signal transmission
- Positioning: Selective Nav1.8 inhibition is a sought‑after approach in non‑opioid analgesic development, aiming to deliver pain relief without the central side effects associated with conventional analgesics
AbbVie Licensing Deal Background
| Item | Detail |
|---|---|
| Deal Date | April 2026 |
| Assets | HSK51155 + another analgesic candidate |
| Licensee | AbbVie |
| Potential Total Value | Exceeding USD 700 million |
The NMPA clinical approval marks a key execution milestone under the partnership, validating the development path of the asset AbbVie chose to license.
Market Impact & Outlook
- Non‑Opioid Analgesia Race: Nav1.8 inhibitors are among the most closely watched mechanisms in the hunt for effective non‑opioid pain therapies, a market with enormous unmet need in both China and the U.S.
- Deal Validation: Clinical clearance in China de‑risks the program backing Haisco Pharmaceutical’s USD 700 million‑plus AbbVie partnership, strengthening confidence in the pipeline that attracted one of the world’s largest immunology and neuroscience players.
- Global‑China Dual Track: With AbbVie holding licensed rights and Haisco advancing its own NMPA‑cleared trials, HSK51155 now has parallel development pathways that could accelerate global readouts.
- Watch Items: First‑in‑human safety and pharmacokinetic data, trial design for pain indications, and AbbVie’s global development timeline for the licensed program.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development, regulatory outcomes, and commercial expectations for HSK51155. Actual results may differ due to risks including early‑stage clinical uncertainty, regulatory decisions, and competitive dynamics in analgesic drug development.-Fineline Info & Tech